Overview

The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

The hypothesis is to test to see if the drug fenofibrate will increase important chemicals in the body and specifically in the kidney, help to rid the body of salt by the kidneys, decrease blood pressure and improve insulin sensitivity during high-salt intake in individuals with hypertension.

Phase:

Phase 4

Details

Lead Sponsor:

Vanderbilt University
Vanderbilt University Medical Center

Collaborator:

National Institutes of Health (NIH)

Treatments:

Fenofibrate